Umbralisib
Umbralisib, also known as TGR1202 and RP5264 , is a highly specific, orally available, PI3K delta inhibitor, targeting the delta isoform with nanomolar potency and several fold selectivity over the alpha, beta, and gamma isoforms of PI3K. Inhibition of PI3K delta signaling with TGR-1202 has demonstrated robust activity in numerous pre-clinical models and primary cells from patients with hematologic malignancies.
For research use only. We do not sell to patients.
Chemical Information
| Name | Umbralisib |
|---|---|
| Iupac Chemical Name | (S)-2-(1-(4-amino-3-(3-fluoro-4-isopropoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-chromen-4-one |
| Synonyms | TGR1202; TGR 1202; TGR-1202; RP5264; RP 5264; RP-5264; Umbralisib. |
| Molecular Formula | C31H24F3N5O3 |
| Molecular Weight | 571.55 |
| Smile | O=C1C(C2=CC=CC(F)=C2)=C([C@@H](N3C4=NC=NC(N)=C4C(C5=CC=C(C(F)=C5)OC(C)C)=N3)C)OC6=CC=C(F)C=C16 |
| InChiKey | IUVCFHHAEHNCFT-INIZCTEOSA-N |
| InChi | InChI=1S/C31H24F3N5O3/c1-15(2)41-24-9-7-18(12-22(24)34)27-26-30(35)36-14-37-31(26)39(38-27)16(3)29-25(17-5-4-6-19(32)11-17)28(40)21-13-20(33)8-10-23(21)42-29/h4-16H,1-3H3,(H2,35,36,37)/t16-/m0/s1 |
| CAS Number | 1532533-67-7 |
| Related CAS | 1532533-67-7 |
Ordering Information
| Packaging | Price | Availability | Purity | Shipping Time |
|---|---|---|---|---|
| Bulk | Enquiry | Enquiry | Enquiry |
| Formulation | Off-white solid |
|---|---|
| Purity | 98% Min. |
| Storage | Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years). |
| Solubility | Soluble in DMSO |
| Handling | Refer to MSDS |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| HS Code | 2934200090 |
| Targets | PI3K delta inhibitor |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |
1: Deng C, Lipstein MR, Scotto L, Jirau Serrano XO, Mangone MA, Li S, Vendome J,
Hao Y, Xu X, Deng SX, Realubit RB, Tatonetti NP, Karan C, Lentzsch S, Fruman DA,
Honig B, Landry DW, O'Connor OA. Silencing c-Myc translation as a therapeutic
strategy through targeting PI3K delta and CK1 epsilon in hematological
malignancies. Blood. 2016 Oct 26. pii: blood-2016-08-731240. [Epub ahead of
print] PubMed PMID: 27784673.
2: Locatelli SL, Careddu G, Inghirami G, Castagna L, Sportelli P, Santoro A,
Carlo-Stella C. The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab
Vedotin-induced Hodgkin lymphoma cell death via mitotic arrest. Leukemia. 2016
Sep 2. doi: 10.1038/leu.2016.224. [Epub ahead of print] PubMed PMID: 27499137.
3: Brown JR. The PI3K pathway: clinical inhibition in chronic lymphocytic
leukemia. Semin Oncol. 2016 Apr;43(2):260-4. doi:
10.1053/j.seminoncol.2016.02.004. Review. PubMed PMID: 27040704.
Chemical Structure
